# SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia

> **NCT03409250** · PHASE4 · COMPLETED · sponsor: **Vista Klinik** · enrollment: 20 (actual)

## Conditions studied

- Choroidal Neovascularization
- Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab, Lucentis

## Key facts

- **NCT ID:** NCT03409250
- **Lead sponsor:** Vista Klinik
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409250, "SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03409250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*